Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.8.0.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Income Statement [Abstract]    
Research and development revenue $ 2,408 $ 0
Grant revenue 987 1,880
Total revenue 3,395 1,880
Operating expenses:    
Research and development 9,487 8,017
General and administrative 11,755 4,482
Total operating expenses 21,242 12,499
Loss from operations (17,847) (10,619)
Interest and other income, net 51 19
Interest expense (853) (431)
Change in fair value of warrant liabilities 128 3
Loss on conversion of notes (4,619) 0
Net loss (23,140) (11,028)
Deemed dividends on preferred stock (958) (1,572)
Net loss attributable to common shareholders $ (24,098) $ (12,600)
Net loss per share attributable to common shareholders:    
Basic and diluted $ (2.11) $ (59.04)
Weighted average number of shares used in net loss per share calculations:    
Basic and diluted 11,400,881 213,420
Other comprehensive loss:    
Unrealized gain (loss) on available-for-sale securities   $ 0
Comprehensive loss $ (24,098) $ (12,600)